## McMillanShakespeareGroup

## ASX ANNOUNCEMENT

## **Board changes**

McMillan Shakespeare Limited Chairman Tim Poole today announced that Sue Dahn has decided not to stand for re-election at the Company's upcoming Annual General Meeting and will retire from the Board with effect from 30 September 2018.

Ms Dahn has been a member of the McMillan Shakespeare Board since January 2016 and is currently the Chair of the Company's Audit, Risk and Compliance Committee.

Mr Poole said "Sue has added great value to McMillan Shakespeare during the last three years and has been a highly effective leader of our Audit, Risk and Compliance Committee. We thank Sue for her contribution and wish her the very best for the future."

Mr Poole also announced the appointment of Helen Kurincic as an independent Non-Executive Director of the Company with effect from 15 September 2018.

Ms Kurincic was formerly the Chief Operating Officer and a Director of Genesis Care from its earliest inception, creating and developing the first and largest radiation oncology and cardiology business across Australia. She is currently the Non-Executive Chair of Integral Diagnostics Limited and is a Non-Executive Director of Estia Health Limited, Sirtex Medical Limited and HBF Health Limited.

Mr Poole said "We are delighted that Helen has agreed to join the Board of McMillan Shakespeare. She is a highly experienced executive and director of ASX listed and unlisted companies with a deep understanding in the health, government and not for profit sectors."

Ms Kurincic will join the Company's Audit, Risk and Compliance Committee and Remuneration and Nomination Committee and will stand for election at the Company's Annual General Meeting on 23 October 2018.

For more information please contact:

Mark Blackburn

CFO and Company Secretary McMillan Shakespeare Limited

ABN 74 107 233 983 AFSL No. 299054 Phone: +61 3 9097 3273 Web: www.mmsg.com.au